Company: ARWR
Filing Date: 2025-01-29
Form Type: DEF 14A
Source: 0001628280-25-002848
Chunk: 49

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: DEF 14A
Chunk 49
---
/2023 |     |                                 |   | 45,000 |     |                        |   871,650 |   |     |                                                                   |     |       — |     |   |                                       |          — |   |
|                      |     |       |     | 01/04/2024 |     |                                 |   | 75,000 |     |                        | 1,452,750 |   |     |                                                                   |     |       — |     |   |                                       |          — |   |
| Javier San Martin    |     |       |     | 01/04/2024 |     |                                 | — |        |     |                        |         — |   |     |                                                                   |     |       — |     |   |                                       |            | — |
| Tracie Oliver        |     |       |     | 07/01/2022 |     |                                 |   | 35,000 |     |                        |   677,950 |   |     |                                                                   |     |       — |     | — |                                       |            | — |
|                      |     |       |     | 01/04/2023 |     |                                 |   |    375 |     |                        |     7,264 |   |     |                                                                   |     |       — |     | — |                                       |            | — |
|                      |     |       |     | 01/04/2024 |     |                                 |   | 75,000 |     |                        | 1,452,750 |   |     |                                                                   |     |       — |     | — |                                       |            | — |

| 47 |

2025 PROXY STATEMENT (1) RSUs have various vesting parameters but generally vest in four equal annual installments beginning one year from the grant date. (2) Value is based on our Company’s Common Stock closing price of $19.37 on September 30, 2024. (3) The amounts reported for Christopher Anzalone in this column reflect the January 2020, January 2021, July 2022, December 2022, and December 2023 awards that contain performance-based vesting conditions. These awards and their vesting conditions are described above in the “Compensation Discussion and Analysis” under the heading “Equity Compensation" in this year’s proxy statement and in prior proxy statements, as applicable.

| 48 |

2025 PROXY STATEMENT Executive